TWSE and SparkLabs Collaborate to Focus on AI Clinical Applications and New Capital Market Opportunities

Spark Labs Taiwan

#SparkLabsTaiwan #創投 #新創投資

The "Smart Medical Industry Salon," co-hosted by the Taiwan Stock Exchange (TWSE) and the international venture capital and startup accelerator SparkLabs Taiwan, was held on December 18 in Taipei. The event brought together heavyweights from hospital systems, international pharmaceutical companies, cloud and AI technology firms, and venture capital accelerators. The salon focused on the global wave of medical technology, exploring real-world AI implementation cases in drug discovery, clinical care, and hospital digital transformation. It also analyzed how smart medical enterprises can accelerate scaling from a capital market perspective to build a complete innovation ecosystem spanning technology, fields, and capital markets.

Capital Markets Supporting Innovation Momentum

In his opening remarks, TWSE Chairman Sherman Lin stated that Taiwan's long-standing advantages in the semiconductor and ICT industries provide the inherent conditions to transform "technological capability" into "medical value." The mission of the capital market is to provide long-term funding for this innovation momentum, creating a sustainable growth curve. Chairman Lin emphasized that the Innovation Board and the Asia Innovation Fundraising Platform will allow the global capital market to see high-quality Taiwanese companies in the smart medical field.

To more effectively support innovative industries including smart medical, following the launch of "Innovation Board 2.0" earlier this year which opened participation to all investors, the TWSE has included Innovation Board stocks as eligible targets for day trading since November 17. Combined with existing odd-lot trading, margin trading, and securities lending mechanisms, the trading system is now fully aligned with the Main Board. The Innovation Board aims to send a clear message to forward-looking industries: "As long as a company possesses an international vision and growth potential, joining the Innovation Board is the starting line for formally entering the capital market and amplifying influence, not a waiting area."

AI Implementation and Growth Paths

The keynote speeches and forums focused on the practical application and growth paths of AI in various segments of smart medical care.

• Organon: Howard Chang, Executive Director of Global Decision Science and AI, used international pharmaceutical companies as an example to explain how AI is being introduced into drug discovery and workflows, and shared the impact of AI on the long-term structure and value chain of the medical industry.

• DTC Digital Technology: Sales Director Lin Li introduced how to assist medical groups in digital transformation.

• Jubo: Founder and CEO Dr. Kang Shih-chung shared practical experience in the commercialization and scaled growth of smart long-term care services, using Jubo’s journey from POC to exceeding 10,000,000 users as an example.

From Laboratory to Market

The highlight of the event was a panel discussion featuring SparkLabs Taiwan, international pharmaceutical companies, heads of biomedical departments from global AI chip giants, and medical AI startups, discussing how smart medical moves from the lab to the market. Edgar Chiu, Co-founder and Managing Partner of SparkLabs Taiwan, stated: "The value of AI in the medical field lies not only in technology but in its actual implementation in clinical, process, and care settings. The Innovation Board serves as the starting line for forward-looking industries to formally enter the capital market, accelerating the transition of Taiwan's smart medical enterprises from R&D to large-scale commercialization."

Since its launch in 2021, the Innovation Board has targeted forward-looking fields such as semiconductors, AI, smart manufacturing, green energy, smart medical, and unmanned vehicles, striving to be the best stage for innovative and growth-oriented enterprises. The TWSE will respond to the government's "Asia Innovation Fundraising Platform" policy through the Innovation Board, continuing to build a smart medical capital ecosystem and assisting Taiwanese innovative enterprises to stand out on the international stage.

Image source：經濟日報